Aptevo Therapeutics Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|
| Revenue | $23.1M | $14.7M | $10.0M | $33.6M |
| Cost of Revenue | $11.2M | $5.0M | $12.5M | $16.9M |
| Gross Profit | $11.9M | $9.6M | $-2.5M | $16.7M |
| Gross Margin | 51.4% | 65.8% | -24.9% | 49.6% |
| Operating Expenses | ||||
| Research & Development | $35.4M | $29.0M | $29.1M | $34.7M |
| SG&A Expense | $28.1M | $34.6M | $36.2M | $43.0M |
| Operating Income | $-51.7M | $-53.9M | $-138.8M | $-61.1M |
| Operating Margin | -224.0% | -368.1% | -1,389.8% | -181.8% |
| Interest Expense | — | — | — | — |
| Pretax Income | $-53.7M | $-55.9M | $-139.6M | $-61.3M |
| Income Tax Expense | — | $-23.3M | $-19.7M | $-2.0M |
| Net Income | $-53.7M | $7.0M | $-112.4M | $-59.3M |
| Net Margin | -232.8% | 47.6% | -1,125.8% | -176.5% |
| EPS (Basic) | $-1.20 | $0.17 | $-2.78 | $-1.47 |
| EPS (Diluted) | $-1.20 | $0.17 | $-2.78 | $-1.47 |
| Shares Outstanding (Basic) | 45.6M | 43.2M | 40.5M | 0 |
| Shares Outstanding (Diluted) | 45.6M | 43.2M | 40.5M | 0 |
| Dividends Per Share | — | — | — | — |